Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2015-001763-39 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ICON plc | INDUSTRY |
| Clinscience Sp. z o.o. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study evaluates the long term effects of E. coli strain Nissle 1917 (EcN-Suspension) probiotic bacteria administration on the number of both, bacterial and viral infections during the first 24 months of infant's life. Half of study participants will receive EcN-Suspension, while the other half will receive placebo. In an additional non-clinical explorative evaluation will furthermore be investigated whether the early intestinal colonization with E.coli strain Nissle 1917 affects the establishment of the intestinal microbiota.
In the course of the present trial the participants will be observed during the first 24 months of life, starting right after birth.
All newborns meeting all inclusion criteria and non-fulfilling any exclusion criteria will be included into the trial. Each participant of this clinical trial will be randomly allocated to one of the two trial arms, by using the method of randomly permuted blocks.
The newborns will be primarily treated during the first three weeks of life and re-treated after 6 and 12 months according to trial interventional plan.
Data on the efficacy and safety will be recorded during control visits after first month, 6, 12, 18 and 24 months.
A follow-up examination of study participants will be performed two years after the end of the participation in the present trial (i.e. at an age of 48 months), during which each child will be examined for its normal physical and cognitive development (covered by the U8 standardized examination). In addition data on allergic/atopic complaints or symptoms will be recorded.
In an additional non-clinical explorative evaluation, it will furthermore be investigated whether the early intestinal colonization with E.coli strain Nissle 1917 affects the establishment of the intestinal microbiota. Therefore stool samples of study participants will be collected at an age of 24 and 48 months. The microbial composition of these samples will be characterized and compared between the two trial arms (EcN vs. placebo).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EcN-Suspension | Experimental | 279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with EcN-Suspension |
|
| Placebo | Placebo Comparator | 279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EcN-Suspension | Drug | Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks). Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day). |
| Measure | Description | Time Frame |
|---|---|---|
| Number of infections | The total number of infections observed for each participant during its individual study participation standardised per month during the first 24 months of life. An infection is an episode of illness caused by:
The duration of an episode of illness is defined as the time from the appearance of the first symptom of a study relevant infection to the disappearance of the last symptom. Infections that occur concurrently or one after another within a period of 7 days are only counted separately, if they belong to different groups of illness. All rhinitides that occur in the first year of a child's life are considered for the count of the primary efficacy variable. Rhinitides that occur in the second year will only be included if they were accompanied by fever (body temperature higher than 38.4°C during at least one measure). | during the first 24 months of life |
| Measure | Description | Time Frame |
|---|---|---|
| Severity of the course of infections considered as primary variables quantified as the "duration of infections" | duration of infection = the number of days with at least one symptom | during the first 24 months of infants' life |
| Severity of the course of infections considered as primary variables quantified as the "number of hospital admissions caused by infections" |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Corinna Wolff, Dipl-Biophys | Ardeypharm GmbH | Study Director |
| Dirk M Olbertz, MD | Klinikum Südstadt Rostock - Abteilung für Neonatologie | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Krankenhaus St. Elisabeth & St. Barbara | Halle | 06110 | Germany | |||
| Universitätsklinikum Jena - Klinik für Kinder- und Jugendmedizin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Placebo | Drug | Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks). Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day). |
|
number of hospital admissions caused by infections |
| during the first 24 months of infants' life |
| Severity of the course of infections considered as primary variables quantified as the "mean number of in-hospital spent days due to infections" | mean number of in-hospital spent days due to infections | during the first 24 months of infants' life |
| Severity of the course of infections considered as primary variables quantified as the "number of antibiotic treatments due to infections". | number of antibiotic treatments due to infections | during the first 24 months of infants' life |
| Severity of the course of infections considered as primary variables quantified as the "number of adverse events". | number of adverse events | during the first 24 months of infants' life |
| Severity of the course of infections considered as primary variables quantified as the "tolerance to trial medication". | Tolerance of trial medication will be assessed by the investigator and scored "very good", "good", "moderate", or "poor". | during the first 24 months of infants' life |
| Jena |
| 07747 |
| Germany |
| Klinikum Westbrandenburg | Potsdam | 14467 | Germany |
| Klinikum Südstadt Rostock - Abteilung für Neonatologie | Rostock | 18059 | Germany |
| Oddział Kliniczny Noworodków, Wcześniaków z Intensywną Terapią Noworodka wraz z Wyjazdowym Zespołem "N" | Bydgoszcz | 85-168 | Poland |
| Samodzielny Publiczny Dziecięcy Szpital Kliniczny Oddział Kliniczny Neonatologiiul | Warsaw | 02-091 | Poland |